Pharma

Your Article Summary

See Latest Articles

Nexavar in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival
BayNews International, 09/24/09

Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced the full results from their first collaborative group–sponsored randomized, double–blind, placebo controlled Phase II trial showing that Nexavar in combination with the oral chemotherapeutic agent, capecitabine, significantly extended progression–free survival in patients with advanced breast cancer by 74 percent.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
Repligen, 12/10/09

Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
Journal of Clinical Oncology, 12/10/09

Fyi from human genome sciences: gsk initiates second pivotal phase 3 trial for investigational cardiovascular medication darapladib
Human Genome Sciences, 12/10/09

 See all of Drug Trials